VPC-3033
Product Specifications
UNSPSC Description
VPC-3033 is an androgen receptor antagonist. VPC-3033 has a strong androgen DHT replacement potency (IC50: 0.625-2.5 μM), can effectively inhibit androgen receptor transcriptional activity (IC50=0.3 μM), and has a strong androgen receptor degradation ability. In addition, VPC-3033 exhibits significant anti-androgen receptor activity against prostate cancer cells resistant to Enzalutamide (HY-70002)[1].
Target Antigen
Androgen Receptor
Type
Reference compound
Related Pathways
Vitamin D Related/Nuclear Receptor
Field of Research
Cancer; Endocrinology
Assay Protocol
https://www.medchemexpress.com/vpc-3033.html
Smiles
O=C1C2=C(/C(C3=C1C=CC=C3)=C\C4=CC(O)=CC=C4)C=CC=C2
Molecular Weight
298.33
References & Citations
[1]Li H, et al. Characterization of a new class of androgen receptor antagonists with potential therapeutic application in advanced prostate cancer[J]. Molecular cancer therapeutics, 2013, 12(11): 2425-2435.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-118409/VPC-3033-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-118409/
Clinical Information
No Development Reported
CAS Number
110763-24-1
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
32491121 3 x 1.0μg DNA
OIT3 CRISPRa sgRNA lentivector (set of three targets)(Human)
Ask
View Details 
MBS7030341-01 0.02 mg
Recombinant Danio rerio Serine palmitoyltransferase small subunit B (sptssb)
Ask
View Details 
MBS7030341-02 0.1 mg
Recombinant Danio rerio Serine palmitoyltransferase small subunit B (sptssb)
Ask
View Details 
MBS7030341-03 5x 0.1 mg
Recombinant Danio rerio Serine palmitoyltransferase small subunit B (sptssb)
Ask
View Details